In Brief: Gilead Forvade
Executive Summary
Gilead Forvade: Cidofovir gel NDA for refractory herpes simplex virus infection in AIDS patients accepted for review by FDA on Jan. 6, company says. Gilead began submitting data packages to FDA in October. Forvade is available through an expanded access program for acyclovir-unresponsive HSV infection in AIDS patients that began in December...